BIO-Europe® 2016: Denali deal and F-star’s innovative asset centric business model

November 24, 2016
Jane Dancer, chief business officer at F-star—a Cambridge, UK-based biotech—chats with Mike Ward, global director of content for Informa Pharma Intelligence, on the sidelines of the recent BIO-Europe® partnering conference in Cologne, Germany. The pair discusses F-star's asset-centric business strategy, the company's recent deal with Denali Therapeutics and when we might see another spinout business from F-Star. The company’s recent deal is the subject of a deal case study at The One Nucleus Genesis meeting in London on December 1, 2016.
Previous Video
Richard Mason – Innovation Head for Europe, Head of Johnson & Johnson Innovation, London
Richard Mason – Innovation Head for Europe, Head of Johnson & Johnson Innovation, London

Next Video
BIO-Europe® 2016: BioNTech's Sean Marett explains Genentech deal rationale
BIO-Europe® 2016: BioNTech's Sean Marett explains Genentech deal rationale

Chief operating officer of BioNTech, Sean Marett, talks to Mike Ward, global director of content for Inform...